Skip to main content
AYTU BIOPHARMA, INC logo

AYTU BIOPHARMA, INC — Investor Relations & Filings

Ticker · AYTU ISIN · US0547548745 US Manufacturing
Open in API
Filings indexed 890 across all filing types
Latest filing 2025-02-12 Interim / Quarterly Rep…
Country US United States of America
Listing US AYTU

About AYTU BIOPHARMA, INC

https://aytubio.com/

Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on developing and commercializing novel therapeutics. The company concentrates on advancing innovative medicines for complex central nervous system (CNS) diseases, with a particular emphasis on treatments for Attention-Deficit/Hyperactivity Disorder (ADHD) and Major Depressive Disorder (MDD). Its business model involves identifying, acquiring, and commercializing new products to improve the quality of life for patients with unmet medical needs.

Recent filings

Filing Released Lang Actions
FORM 10-Q
Interim / Quarterly Report Q2 2025
2025-02-12 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 12, 2025. It announces the issuance of a press release regarding the company's fiscal 2025 second quarter operational and financial results and the scheduling of a conference call to discuss these results. The document includes a press release as an exhibit but does not contain the full financial statements or detailed financial data itself. It primarily serves as an announcement of the earnings release and related conference call, not the earnings release document itself. Therefore, it fits the category of Earnings Release (ER) as it is the initial announcement of quarterly financial results with key highlights and a conference call notice.
2025-02-12 English
Director's Dealing 2025
Director's Dealing
2025-01-02 English
FORM 8-K
Legal Proceedings Report Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated December 3, 2024, by Aytu BioPharma, Inc. It announces a scheduled court hearing related to a settlement of derivative claims and includes a Notice of Pendency of Derivative Action and Proposed Settlement as an exhibit. The content is primarily a regulatory disclosure about legal proceedings and settlement status, not a full financial report or earnings release. The document length is 4500 characters, which is relatively short and focused on a specific event. The key content relates to legal matters and settlement notices, which aligns with Legal Proceedings Report filings. Therefore, the appropriate classification is Legal Proceedings Report (LTR).
2024-12-04 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-11-13 English
FORM 10-Q
Interim / Quarterly Report Q1 2025
2024-11-13 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.